ALS Drug COYA 302 Moves Into Extended Trial Phase Targeting Immune Inflammation
Coya Therapeutics advances its ALS trial as all patients now receive COYA 302, a therapy designed to calm immune-driven nerve damage.
Summary
Coya Therapeutics has moved its experimental ALS drug, COYA 302, into an extended treatment phase of its Phase 2 clinical trial. All enrolled patients now receive the active drug for an additional 24 weeks, giving researchers up to 48 weeks of total data. COYA 302 combines low-dose interleukin-2 with CTLA-4 Ig, two agents that work together to boost regulatory T cells — immune cells that help control harmful inflammation. In ALS, runaway inflammation from activated immune cells contributes to the progressive destruction of motor neurons. By dampening this inflammatory process, COYA 302 aims to slow or halt disease progression. The trial is randomized, double-blind, and placebo-controlled, representing a rigorous standard of evidence. The drug remains investigational and has not yet received FDA approval.
Detailed Summary
Amyotrophic lateral sclerosis, or ALS, is a fatal neurodegenerative disease that destroys the motor neurons controlling movement. Neuroinflammation — driven by overactive immune cells called monocytes and macrophages — plays a significant role in accelerating this damage. Coya Therapeutics is betting that correcting this immune imbalance could meaningfully alter the course of the disease.
The company has now transitioned its ALSTARS trial (NCT07161999) into a blinded active-treatment extension phase. Patients who completed the initial 24-week double-blind, placebo-controlled period have all moved onto COYA 302, with former placebo recipients re-randomized into one of two dosing regimens. This design will provide up to 48 weeks of cumulative data on the drug's safety and efficacy profile.
COYA 302 is a proprietary combination of low-dose interleukin-2 (IL-2) and CTLA-4 Ig. Low-dose IL-2 is known to selectively expand regulatory T cells (Tregs), which are critical immune modulators that suppress excessive inflammatory responses. CTLA-4 Ig complements this by directly inhibiting activation of the inflammatory monocytes and macrophages implicated in ALS neurodegeneration. Together, these mechanisms aim to restore immune balance in a system that has turned against the nervous system.
For the broader longevity and healthspan community, this trial is notable because neuroinflammation and immune dysregulation are increasingly recognized as central drivers of aging-related decline — not just in ALS but across neurodegenerative conditions including Alzheimer's and Parkinson's. Treg-enhancing strategies like low-dose IL-2 are being explored in multiple aging-adjacent contexts.
Important caveats apply. COYA 302 remains investigational and unapproved. This update is a trial milestone announcement, not a results disclosure — no efficacy or safety data has been published from this study. Full trial data will be needed before drawing conclusions about the drug's clinical value.
Key Findings
- All ALSTARS trial participants now receive COYA 302, extending treatment data collection to up to 48 weeks.
- COYA 302 combines low-dose IL-2 and CTLA-4 Ig to boost regulatory T cells and reduce neuroinflammation.
- Overactive monocytes and macrophages drive ALS progression; COYA 302 specifically targets this immune pathway.
- The Phase 2 trial uses a rigorous double-blind, placebo-controlled, multi-center design.
- Treg-enhancing therapies like low-dose IL-2 are emerging across multiple neurodegeneration and aging research areas.
Methodology
This is a news report summarizing a clinical trial milestone announcement from Coya Therapeutics, published by Longevity.Technology. It is based on a company press release and does not present peer-reviewed data or published trial results. Evidence basis is limited to company-reported trial design information.
Study Limitations
No efficacy or safety results have been released from this trial — this update covers trial progression only, not outcomes. The article is based on a company announcement and may reflect promotional framing. Independent peer-reviewed publication of trial data is needed before conclusions about COYA 302's effectiveness can be drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.